Insilico Medicine presents four posters featuring AI-designed anti-cancer drugs at AACR
Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that four abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023.
Insilico will present four novel inhibitors for the treatment of cancer developed with its end-to-end Pharma.AI platform. Drawing from trillions of data points and millions of compounds and molecular fragments, the platform uses ...












